The Changing Face of Advanced Prostate Cancer Webcast (2023)

This is an ongoing course on advanced prostate cancer at the AUA Annual Meeting since 2012, and the changes over the last decade have been nothing less than breathtaking! In the early years, it was all about metastatic castrate-resistant prostate cancer (CRPC) with multiple new therapeutic advances starting in 2010, followed by abiraterone and enzalutamide and a focus on bone-targeted agents. Later, the course expanded to cover hormone-sensitive (HS) advanced disease due to the new data on docetaxel and abiraterone extending survival in new M1 patients In 2017, and the topic of nonmetastatic CRPC (M0 CRPC) was added due to emerging data on use of apalutamide and enzalutamide in these men. In 2019, before COVID, the course expanded information on HS new M1 disease with emerging data that four agents (docetaxel, abiraterone, apalutamide and enzalutamide) all improve survival for men with new metastatic prostate cancer. Some may have argued that the value of the course for urologists was a stretch back in 2012 because of the belief by some physicians that metastatic CRPC should be managed only by medical oncologists. However, over the last few years, the course is even more relevant to practicing urologists as most M0 CRPC and virtually all new M1 HS patients are initially managed by urologists. Using a case-based and multidisciplinary format, we will continue to push the boundaries of knowledge to urologists and their teams in covering this new toolbox of novel therapies. In addition, we will cover the latest advance in lutetium prostate-specific membrane antigen 617 (VISION and Thera-P Trials) , molecular genetic profiling, PARP inhibitors and the latest in “triple” therapy for HS M1 disease


Independent educational grant support provided by:

  • Astellas
  • AstraZeneca
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Lantheus Medical Imaging
  • Merck & Co., Inc.
  • Pfizer, Inc.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Identify and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT), offer either enzalutamide or apalutamide or abiraterone acetate and recognize high-volume new M1 prostate cancer to refer to a genitourinary medical oncologist for docetaxel chemotherapy if necessary.
  2. Diagnose M0 metastatic CRPC, educate patients about using either enzalutamide or apalutamide or darolutamide added to traditional ADT as a way to improve their patent’s overall and radiographic progression-free survival, and explain the differences between these three oral agents to educate patients about side effects and toxicities.
  3. Describe the latest phase III randomized controlled trial results for new therapies in M1 CRPC, educate patients on treatment options and work on a multidisciplinary team caring for this disease state of far advanced prostate cancer.
  4. Explain that advanced prostate cancer is a complex group of disease states with rapidly changing therapeutic landscape and the need for providers and teams to embrace the multidisciplinary nature of this care for our patients.
  5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Lawrence I. Karsh, MD, FACSMyriad GeneticsConsultant or Advisor08/17/2021
 OPKOConsultant or Advisor08/17/2021
 CepheidScientific Study or Trial08/17/2021
 NucleixScientific Study or Trial08/17/2021
 MinomicScientific Study or Trial08/17/2021
 NeoGenomic LaboratoriesScientific Study or Trial08/17/2021
 ABBVIEConsultant or AdvisorCurrent
 AstellasScientific Study or TrialCurrent
 Astra-ZenecaConsultant or AdvisorCurrent
 AugmenixScientific Study or Trial08/17/2021
 BayerScientific Study or TrialCurrent
 BioXcelScientific Study or Trial09/01/2022
 Boston ScientificConsultant or Advisor08/17/2021
 Bristol Myers SquibbScientific Study or TrialCurrent
 ClovisConsultant or Advisor09/28/2022
 DendreonScientific Study or TrialCurrent
 EMD SeronoConsultant or Advisor08/17/2021
 EpizymeScientific Study or TrialCurrent
 Exact SciencesScientific Study or Trial12/01/2022
 ExelexisScientific Study or Trial09/28/2022
 FKDScientific Study or TrialCurrent
 Genetech/HoffmanScientific Study or Trial09/28/2022
 Genomic HealthScientific Study or Trial01/03/2022
 HinovaScientific Study or Trial12/30/2022
 JanssenScientific Study or TrialCurrent
 KiadisConsultant or Advisor09/28/2022
 MerckConsultant or AdvisorCurrent
 MyovantConsultant or AdvisorCurrent
 NeusperaScientific Study or TrialCurrent
 NymoxScientific Study or Trial08/17/2021
 PfizerConsultant or AdvisorCurrent
 QEDScientific Study or Trial09/28/2022
 SesenConsultant or Advisor09/28/2022
 SiemansScientific Study or Trial08/17/2021
 TavantaScientific Study or TrialCurrent
 TolmarConsultant or Advisor12/01/2021
 UrogenConsultant or Advisor09/28/2022
 Veru PharmaceuticalsScientific Study or Trial08/17/2021
David Scott Morris, MD, FACSAstellasConsultant or AdvisorCurrent
 AstraZenecaConsultant or AdvisorCurrent
 BayerConsultant or AdvisorCurrent
 ClovisConsultant or Advisor44896
 Decipher BioConsultant or AdvisorCurrent
 DendreonConsultant or Advisor12/31/2021
 InvitaeScientific Study or Trial12/31/2022
 JanssenConsultant or AdvisorCurrent
 LantheusConsultant or AdvisorCurrent
 MerckConsultant or AdvisorCurrent
 MyovantConsultant or AdvisorCurrent
 MyriadConsultant or AdvisorCurrent
 Pacific Edge DiagnosticsConsultant or Advisor44561
 PfizerMeeting Participant or LecturerCurrent
 ProgenicsConsultant or Advisor44964
 TolmarConsultant or AdvisorCurrent
 UroGen PharmaConsultant or AdvisorCurrent
Alicia Morgans, MDAdvanced Accelerator ApplicationsConsultant or AdvisorCurrent
 AstellasConsultant or AdvisorCurrent
 Astra ZenecaConsultant or AdvisorCurrent
 BayerConsultant or AdvisorCurrent
 BMSConsultant or AdvisorCurrent
 ClovisConsultant or Advisor12/30/2021
 DendreonConsultant or AdvisorCurrent
 GenetechConsultant or Advisor12/30/2021
 JanssenConsultant or AdvisorCurrent
 LantheusConsultant or AdvisorCurrent
 MerckConsultant or AdvisorCurrent
 MyovantConsultant or AdvisorCurrent
 MyriadConsultant or AdvisorCurrent
 NovartisConsultant or AdvisorCurrent
 PfizerConsultant or AdvisorCurrent
 ProgenicsConsultant or Advisor12/30/2021
 SanofiConsultant or AdvisorCurrent
 TelixConsultant or AdvisorCurrent
Judd W. Moul, MD, FACSSanofi-AventisMeeting Participant or LecturerCurrent
 TheralogixConsultant or AdvisorCurrent
 Janssen- J and JMeeting Participant or LecturerCurrent
 PfizerScientific Study or TrialCurrent
 AstellasMeeting Participant or LecturerCurrent
 TolmarConsultant or AdvisorCurrent
 Exosome DxMeeting Participant or LecturerCurrent
 Blue Earth DiagnosticsMeeting Participant or LecturerCurrent
 BayerConsultant or AdvisorCurrent
 DendreonMeeting Participant or LecturerCurrent



PDF icon Education Council Disclosures_2022.pdf


PDF iconCOI Review Work Group Disclosures_2023_0.pdf


AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.


Learners will participate in this online educational activity by view the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: May, 2023
Expiration Date: May, 2024


The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.


It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.


All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.



All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic



The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.